Onxeo: Combined General Meeting on April 26, 2017

PARIS--()--Regulatory News:

Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO), a biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, announced today that Onxeo’s shareholders are invited to attend the Company’s Combined Ordinary and Extraordinary General Meeting which is being held on Wednesday, April 26, 2017 at 10.00 AM CET at Onxeo’s headquarters: 49 Boulevard du Général Martial Valin, 75015 Paris, France.

The official notice of the General Meeting was published in the French Republic’s Bulletin des Annonces Légales Obligatoires (i.e. the “Bulletin of Mandatory Legal Announcements”) on March 22, 2017 and includes the agenda, the draft resolutions, and information on attendance and voting procedures. Under the conditions set out in current legislation, you can find the notice in its full length, together with all other related documents, on Onxeo’s website: http://www.onxeo.com/en/investisseurs/assemblee-generale/

The above-mentioned documents are available to shareholders at the company’s headquarters and on the Company’s website. Shareholders may request to receive the documents by sending their request and postal or email address to Onxeo either by airmail (Direction Financière – 49 Boulevard du Général Martial Valin, 75015 Paris, France), fax (+33 1 45 58 08 81), or email (investors@onxeo.com)

About Onxeo

Onxeo is a biotechnology company developing innovative drugs for the treatment of orphan diseases in oncology, driven by high therapeutic demand in one of the fastest growing segments of the pharmaceutical industry.
Onxeo’s objective is to become a major international player in the field of rare cancers. Its growth strategy is founded on the development of innovative, effective, and safe drugs based on breakthrough technologies that can make a real difference in the treatment of orphan oncology diseases and considerably improve the quality of life of patients affected by rare or resistant cancers.

Onxeo’s comprehensive portfolio features a broad orphan oncology pipeline, with 3 major products in several on-going preclinical and clinical programs, alone or in combination for various cancer indications.

The Company is headquartered in Paris, France with offices in Copenhagen and in New York, and has approximately 60 employees. Onxeo is listed on Euronext in Paris, France and Nasdaq Copenhagen, Denmark (Ticker: ONXEO, ISIN Code: FR0010095596).

Learn more by visiting www.onxeo.com

Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2015 Reference Document filed with the AMF on April 29, 2016, which is available on the AMF website (http://www.amf-france.org) or on the company’s website (www.onxeo.com).

Contacts

Onxeo
Valerie Leroy
Investor Relations
+33 1 45 58 76 00
investors@onxeo.com
or
Media Relations
Alize RP
Caroline Carmagnol / Simon Derbanne
+33 6 64 18 99 59 / +33 6 38 16 26 41
onxeo@alizerp.com
or
Investor Relations / Strategic Communications
NewCap
Dušan Orešanský / Emmanuel Huynh
+33 1 44 71 94 92
onxeo@newcap.eu
or
Investor & Media Relations US
The Ruth Group
Kirsten Thomas / Lee Roth
+1 508 280 6592 / +1 646 536 7012
kthomas@theruthgroup.com / lroth@theruthgroup.com

Contacts

Onxeo
Valerie Leroy
Investor Relations
+33 1 45 58 76 00
investors@onxeo.com
or
Media Relations
Alize RP
Caroline Carmagnol / Simon Derbanne
+33 6 64 18 99 59 / +33 6 38 16 26 41
onxeo@alizerp.com
or
Investor Relations / Strategic Communications
NewCap
Dušan Orešanský / Emmanuel Huynh
+33 1 44 71 94 92
onxeo@newcap.eu
or
Investor & Media Relations US
The Ruth Group
Kirsten Thomas / Lee Roth
+1 508 280 6592 / +1 646 536 7012
kthomas@theruthgroup.com / lroth@theruthgroup.com